Is anyone wondering why our CEO hasn’t purchased shares in PAA when we’re all expecting exceptional results from the phase 1 MEND study? I’m aware of performance rights etc but nothing like putting money where one’s mouth is.
Very happy with Dr MT’s performance so far but having skin in the game would be icing on the cake.
Just my thoughts as we finish the year..
Ann: PAA completes Phase 1 and files for Orphan Drug Designation, page-146
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
-0.030(12.8%) |
Mkt cap ! $81.16M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 23.5¢ | 20.5¢ | $276.8K | 1.274M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 134649 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 65000 | 1 |
View Market Depth
| Last trade - 16.10pm 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
21.0¢ |
Change
-0.030 ( 8.70 %) |
||||
| Open | High | Low | Volume | ||
| 22.5¢ | 23.0¢ | 21.0¢ | 615701 | ||
| Last updated 15.56pm 06/06/2024 ? | |||||
| PAA (ASX) Chart |